Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Clinical trial NCT06380751 · RECRUITING

Trial details

NCT number: NCT06380751
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced Breast Cancer

Start date: 2024-08-01
Primary completion: 2029-12-18
Enrollment: 788

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.